+

WO2010067980A3 - Inhibiteur d'histone déacétylase réactivant le provirus vih-1 dans des cellules infectées par le vih latent - Google Patents

Inhibiteur d'histone déacétylase réactivant le provirus vih-1 dans des cellules infectées par le vih latent Download PDF

Info

Publication number
WO2010067980A3
WO2010067980A3 PCT/KR2009/007162 KR2009007162W WO2010067980A3 WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3 KR 2009007162 W KR2009007162 W KR 2009007162W WO 2010067980 A3 WO2010067980 A3 WO 2010067980A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
proviruses
inhibitor
infected cells
latently
Prior art date
Application number
PCT/KR2009/007162
Other languages
English (en)
Korean (ko)
Other versions
WO2010067980A2 (fr
Inventor
홍기종
최병선
김성순
이학성
노성구
현영란
Original Assignee
대한민국(관리부서 질병관리본부장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(관리부서 질병관리본부장) filed Critical 대한민국(관리부서 질병관리본부장)
Priority to KR1020117012184A priority Critical patent/KR101388596B1/ko
Publication of WO2010067980A2 publication Critical patent/WO2010067980A2/fr
Publication of WO2010067980A3 publication Critical patent/WO2010067980A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un inhibiteur d'histone déacétylase (HDAC) de formule chimique 1, qui permet la réactivation du provirus VIH-1 à partir de cellules infectées par le VIH latent. L'invention porte en outre sur un procédé de réactivation du provirus VIH-1 à partir de cellules infectées par le VIH latent au moyen dudit inhibiteur. Ledit HDAC présente une faible toxicité cellulaire et une stabilité élevée, de telle sorte qu'il peut réactiver efficacement le provirus VIH-1 latent à partir du réservoir de cellules CD4+ T. En conséquence, ledit inhibiteur HDAC est traité avec une combinaison de médicaments thérapeutiques HAART, tels que l'AZT inhibiteur de la transcriptase inverse, de sorte que le réservoir de VIH latent peut être réduit ou retiré efficacement.
PCT/KR2009/007162 2008-12-11 2009-12-02 Inhibiteur d'histone déacétylase réactivant le provirus vih-1 dans des cellules infectées par le vih latent WO2010067980A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020117012184A KR101388596B1 (ko) 2008-12-11 2009-12-02 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12190108P 2008-12-11 2008-12-11
US61/121,901 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010067980A2 WO2010067980A2 (fr) 2010-06-17
WO2010067980A3 true WO2010067980A3 (fr) 2010-09-23

Family

ID=42243170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007162 WO2010067980A2 (fr) 2008-12-11 2009-12-02 Inhibiteur d'histone déacétylase réactivant le provirus vih-1 dans des cellules infectées par le vih latent

Country Status (2)

Country Link
KR (1) KR101388596B1 (fr)
WO (1) WO2010067980A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105597090B (zh) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
KR101978364B1 (ko) 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
KR102678356B1 (ko) * 2018-10-29 2024-06-26 씨지인바이츠 주식회사 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 인산염, 타르타르산염 또는 이들의 조합을 포함하는 약제학적 조성물 및 그 제조방법
KR20220118747A (ko) * 2021-02-19 2022-08-26 크리스탈지노믹스(주) 제2형 중증급성호흡기증후군 코로나바이러스 감염증 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (fr) * 2003-02-25 2004-09-10 Topotarget Uk Limited Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
WO2007052938A1 (fr) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Dérivés d’alkylcarbamoylnaphtalényloxyocténoylhydroxyamide présentant une activité inhibitrice vis-à-vis de l'histone désacétylase et synthèse desdits dérivés
WO2008068170A1 (fr) * 2006-12-04 2008-06-12 William Paul Jackson Inhibiteurs de l'hdac

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (fr) * 2003-02-25 2004-09-10 Topotarget Uk Limited Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
WO2007052938A1 (fr) * 2005-11-01 2007-05-10 Korea Research Institute Of Chemical Technology Dérivés d’alkylcarbamoylnaphtalényloxyocténoylhydroxyamide présentant une activité inhibitrice vis-à-vis de l'histone désacétylase et synthèse desdits dérivés
WO2008068170A1 (fr) * 2006-12-04 2008-06-12 William Paul Jackson Inhibiteurs de l'hdac

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YLISASTIGUI, LOYDA ET AL.: "Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression", AIDS, vol. 18, no. ISSUE, 21 May 2004 (2004-05-21), pages 1101 - 1108 *

Also Published As

Publication number Publication date
WO2010067980A2 (fr) 2010-06-17
KR20110096028A (ko) 2011-08-26
KR101388596B1 (ko) 2014-04-24

Similar Documents

Publication Publication Date Title
WO2010067980A3 (fr) Inhibiteur d'histone déacétylase réactivant le provirus vih-1 dans des cellules infectées par le vih latent
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
MX2010005334A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
EA201390794A1 (ru) Бициклическое соединение
EP1564210A4 (fr) Composes 4-oxoquinoliniques et leur utilisation comme inhibiteur de la vih-integrase
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
EA201170960A1 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
WO2012051492A3 (fr) Composés et procédés pour inhiber la latence du vih
MX2010006397A (es) Compuestos heterociclicos antivirales.
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
EA200500322A1 (ru) Соединения дигидропиразолопиридина
EA201270216A1 (ru) Фармацевтический состав
WO2010144378A3 (fr) Composés inhibiteurs de hdac de cycloalkylcarbamate-benzamide-aniline
WO2009055006A8 (fr) Darunavir deutéré
EA201200552A1 (ru) Производные пиримидина в качестве ингибиторов протеинтирозинкиназы 2
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA201490223A1 (ru) Составы на основе дарунавира
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
RS53131B (en) N - ((1R, 2S, 5R) -5- (TERC-BUTYLAMINO) -2 - (S) -3- (7-TERC-BUTYLPYRAZOLO] [1,5-A] [1,3,5] TRIAZIN- 4-YLAMINO) -2-OXOPYROLIDIN-1-YL) CYCLICHEXYL) ACETAMIDE, DUAL MODULATOR OF HEMOKIN RECEPTOR ACTIVITY, CRYSTAL FORMS AND PROCEDURES
WO2012026813A3 (fr) Analogues de géranylgéranylacétone (gga) et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20117012184

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09832066

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载